Jorge D. Gallo
Basel, BS 4070, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer.
Journal: Pharmaceutics
Published: August 26, 2022
Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications.
Journal: Clinical and translational science
Published: August 26, 2022
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 25, 2022
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Journal: Lancet (London, England)
Published: December 07, 2020
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.
Journal: Pigment cell & melanoma research
Published: September 01, 2017
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.
Journal: Cold Spring Harbor molecular case studies
Published: May 06, 2016
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 27, 2015
Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers.
Journal: Clinical pharmacology : advances and applications
Published: February 06, 2015
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 21, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026